CL2019003610A1 - Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). - Google Patents
Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477).Info
- Publication number
- CL2019003610A1 CL2019003610A1 CL2019003610A CL2019003610A CL2019003610A1 CL 2019003610 A1 CL2019003610 A1 CL 2019003610A1 CL 2019003610 A CL2019003610 A CL 2019003610A CL 2019003610 A CL2019003610 A CL 2019003610A CL 2019003610 A1 CL2019003610 A1 CL 2019003610A1
- Authority
- CL
- Chile
- Prior art keywords
- steroid
- crystalline
- pyrazolyl
- disubstituted
- divisional application
- Prior art date
Links
- 150000003431 steroids Chemical class 0.000 title abstract 2
- 239000007787 solid Substances 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
ESTA INVENCIÓN SE REFIERE A UN ESTEROIDE 9-NOR-C21-PIRAZOIIIO C3,3-DISUSTITUIDO DE LA FÓRMULA (1), Y FORMAS SÓLIDA CRISTALINAS Y COMPOSICIONES DEL MISMO. TAMBIÉN SE DESCRIBEN EN LA PRESENTE MÉTODOS DE PREPARACIÓN DE FORMAS SÓLIDAS CRISTALINAS DEL ESTEROIDE 19-NOR-21-PIRAZOLILO C3,3-DISUSTITUIDO DE LA FÓRMULA (1) Y MÉTODOS DE USO DEL ESTEROIDE 1 9-NORC21 -PIRAZOLILO C3,3-DISUSTITUIDO DE LA FÓRMULA (1) O FORMAS SÓLIDAS CRISTALINAS, SALES FARMACÉUTICAMENTE ACEPTABLES, Y COMPOSICIONES FARMACÉUTICAMENTE ACEPTABLES DEL MISMO.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378582P | 2016-08-23 | 2016-08-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2019003610A1 true CL2019003610A1 (es) | 2020-05-22 |
Family
ID=59772778
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000477A CL2019000477A1 (es) | 2016-08-23 | 2019-02-22 | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. |
| CL2019003610A CL2019003610A1 (es) | 2016-08-23 | 2019-12-10 | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2019000477A CL2019000477A1 (es) | 2016-08-23 | 2019-02-22 | Un esteroide 19 nor-c21-n-pirazolilo c3,3- disustituido cristalino. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US11236121B2 (es) |
| EP (2) | EP3981763A1 (es) |
| JP (3) | JP2019524853A (es) |
| KR (2) | KR20230079470A (es) |
| CN (4) | CN115974954A (es) |
| AR (3) | AR109393A1 (es) |
| AU (3) | AU2017315682B2 (es) |
| BR (1) | BR112019003637A2 (es) |
| CA (1) | CA3034262A1 (es) |
| CL (2) | CL2019000477A1 (es) |
| CO (1) | CO2019002596A2 (es) |
| EA (1) | EA201990565A1 (es) |
| EC (1) | ECSP19020141A (es) |
| IL (1) | IL302480A (es) |
| JO (1) | JOP20190022B1 (es) |
| MA (1) | MA46042A (es) |
| MX (2) | MX2019002193A (es) |
| PE (1) | PE20190915A1 (es) |
| PH (1) | PH12019500375A1 (es) |
| SG (1) | SG11201901445TA (es) |
| TW (1) | TWI808945B (es) |
| WO (1) | WO2018039378A1 (es) |
| ZA (1) | ZA201901051B (es) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013056181A1 (en) | 2011-10-14 | 2013-04-18 | Sage Therapeutics, Inc. | 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof |
| JP6355633B2 (ja) | 2012-08-21 | 2018-07-11 | セージ セラピューティクス， インコーポレイテッド | てんかんまたはてんかん重積状態の処置方法 |
| HUE055554T2 (hu) | 2013-04-17 | 2021-12-28 | Sage Therapeutics Inc | 19-nor-C3,3-Diszubsztituált C21-N-pirazolil szteroid terápiában történõ alkalmazásra |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| PL2986624T3 (pl) | 2013-04-17 | 2020-11-16 | Sage Therapeutics, Inc. | Neuroaktywne steroidy 19-NOR do stosowania w sposobach leczenia |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| CN105555277B (zh) | 2013-07-19 | 2022-01-11 | 萨奇治疗股份有限公司 | 神经活性类固醇化合物、组合物及其用途 |
| RS61370B1 (sr) | 2013-08-23 | 2021-02-26 | Sage Therapeutics Inc | Neuroaktivni steroidi, njihove kompozicije i upotreba |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| SG10202009861SA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| CA2964898A1 (en) | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3224269B1 (en) | 2014-11-27 | 2020-02-26 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| PL3250210T3 (pl) | 2015-01-26 | 2021-07-26 | Sage Therapeutics, Inc. | Kompozycje i sposoby leczenia zaburzeń OUN |
| JP6875996B2 (ja) | 2015-02-20 | 2021-05-26 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド、組成物、およびその使用 |
| JP7065825B2 (ja) | 2016-07-11 | 2022-05-12 | セージ セラピューティクス， インコーポレイテッド | Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法 |
| CA3030413A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| AU2018327357B2 (en) * | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| MX2020002889A (es) * | 2017-09-14 | 2020-10-01 | Sage Therapeutics Inc | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo. |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3806863A1 (en) * | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| AU2019392680A1 (en) | 2018-12-05 | 2021-06-10 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| CN111454318A (zh) * | 2019-01-20 | 2020-07-28 | 浙江易众化工有限公司 | 抗抑郁药物sage-217的晶型及其制备方法 |
| CN111770915A (zh) * | 2019-01-31 | 2020-10-13 | 深圳仁泰医药科技有限公司 | γ-氨基丁酸调节剂的晶型X及其制备方法和应用 |
| US20220220149A1 (en) | 2019-05-28 | 2022-07-14 | Teva Czech Industries S.R.O | Solid state forms of sage-217 and processes for preparation thereof |
| CA3139554A1 (en) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| US20220275020A1 (en) * | 2019-08-07 | 2022-09-01 | Shanghai Hansoh Biomedical Co., Ltd. | Salt and crystal form of steroid derivative regulator |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| JP2023519241A (ja) | 2020-03-25 | 2023-05-10 | セージ セラピューティクス， インコーポレイテッド | 呼吸器状態の処置のための薬剤の使用 |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2022072620A1 (en) * | 2020-10-01 | 2022-04-07 | Eliem Therapeutics (UK) Ltd | Methods of treating fibromyalgia with neuroactive steroids |
| AU2022214187A1 (en) | 2021-01-28 | 2023-07-13 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| BR112023018607A2 (pt) | 2021-03-17 | 2023-10-24 | Sage Therapeutics Inc | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
| CN117580580A (zh) | 2021-04-29 | 2024-02-20 | 萨奇治疗股份有限公司 | 用于在哺乳期女性中治疗重度抑郁障碍和产后抑郁症的神经活性类固醇 |
| WO2022232504A1 (en) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression |
| BR112024001518A2 (pt) | 2021-07-28 | 2024-04-30 | Sage Therapeutics Inc | Formas cristalinas de um esteroide neuroativo |
| WO2023158668A1 (en) | 2022-02-16 | 2023-08-24 | Sage Therapeutics, Inc. | Neuroactive steroids for treatment of cns-related disorders |
| TW202341996A (zh) | 2022-02-28 | 2023-11-01 | 美商賽吉醫療公司 | 用於治療腸胃疾病或病狀之神經活性類固醇 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| MXPA02006660A (es) | 2000-01-07 | 2002-12-13 | Transform Pharmaceuticals Inc | Formacion, identificacion y analisis de diversas formas solidas de alto rendimiento. |
| NZ534523A (en) | 2002-02-08 | 2006-10-27 | Ono Pharmaceutical Co | Piperidine derivative compounds and drugs containing the compounds as the active ingredient |
| WO2011079047A1 (en) | 2009-12-23 | 2011-06-30 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| JP2014521662A (ja) | 2011-07-29 | 2014-08-28 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ＧＡＢＡＡ受容体のモジュレーターとしての新規な１７β−ヘテロアリール置換ステロイド |
| WO2013043985A1 (en) | 2011-09-23 | 2013-03-28 | The Regents Of The University Of California | Edible oils to enhance delivery of orally administered steroids |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| PH12018502141A1 (en) | 2012-12-18 | 2019-04-15 | Sage Therapeutics Inc | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| HUE055554T2 (hu) * | 2013-04-17 | 2021-12-28 | Sage Therapeutics Inc | 19-nor-C3,3-Diszubsztituált C21-N-pirazolil szteroid terápiában történõ alkalmazásra |
| US9725481B2 (en) | 2013-04-17 | 2017-08-08 | Sage Therapeutics, Inc. | 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof |
| US10246482B2 (en) | 2014-06-18 | 2019-04-02 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| SG10202009861SA (en) | 2014-10-16 | 2020-11-27 | Sage Therapeutics Inc | Compositions and methods for treating cns disorders |
| CA2964898A1 (en) * | 2014-10-16 | 2016-04-21 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| WO2017044659A1 (en) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| AU2016338672A1 (en) | 2015-10-16 | 2018-04-12 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| US20200306262A1 (en) | 2015-11-20 | 2020-10-01 | Sage Therapeutics, Inc. | Compounds and methods of their use |
| RU2766155C2 (ru) | 2016-03-08 | 2022-02-08 | Сейдж Терапьютикс, Инк. | Нейроактивные стероиды, их композиции и применения |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| CA3030413A1 (en) | 2016-07-11 | 2018-01-18 | Sage Therapeutics, Inc. | C17, c20, and c21 substituted neuroactive steroids and their methods of use |
| JP7065825B2 (ja) | 2016-07-11 | 2022-05-12 | セージ セラピューティクス， インコーポレイテッド | Ｃ７、ｃ１２、およびｃ１６置換神経刺激性ステロイドおよびそれらの使用方法 |
| KR20230079470A (ko) | 2016-08-23 | 2023-06-07 | 세이지 테라퓨틱스, 인크. | 결정질 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| WO2019045121A1 (en) | 2017-08-31 | 2019-03-07 | Takeda Pharmaceutical Company Limited | TREATMENT OF CNS DISEASES |
| AU2018327357B2 (en) | 2017-09-07 | 2024-08-22 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| WO2019051477A1 (en) | 2017-09-11 | 2019-03-14 | Sage Therapeutics, Inc. | METHODS OF TREATING EPILEPSY OR EPILEPTIC MALE CONDITION |
| MX2020002889A (es) | 2017-09-14 | 2020-10-01 | Sage Therapeutics Inc | Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo. |
| EA202091144A1 (ru) | 2017-11-10 | 2020-09-16 | Маринус Фармасьютикалз, Инк. | Ганаксолон для использования в лечении наследственных эпилептических заболеваний |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN118085004A (zh) | 2017-12-22 | 2024-05-28 | 萨奇治疗股份有限公司 | 治疗中枢神经系统疾病的组合物和方法 |
| BR112020012712A8 (pt) | 2017-12-22 | 2022-03-03 | Sage Therapeutics Inc | Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos do referido composto para o tratamento de distúrbios do snc |
| JP7538040B2 (ja) | 2018-01-12 | 2024-08-21 | セージ セラピューティクス， インコーポレイテッド | ＣＮＳ障害の処置における使用のためのアザ、オキサ、およびチア－プレグナン－２０－オン－３α－オール化合物 |
| EP3806863A1 (en) | 2018-06-12 | 2021-04-21 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof |
| JP2022504607A (ja) | 2018-10-12 | 2022-01-13 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害の処置において使用するための、１０位において環式基で置換された神経刺激性ステロイド |
| AU2019359899B2 (en) | 2018-10-19 | 2024-07-04 | Sage Therapeutics, Inc. | 9(11)-unsaturated neuroactive steroids and their methods of use |
| AU2019392680A1 (en) | 2018-12-05 | 2021-06-10 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| MX2021007504A (es) | 2018-12-21 | 2021-10-13 | Sage Therapeutics Inc | Esteroides neuroactivos alfa.-hidroxi-17.beta.-amida y composiciones de los mismos. |
| TW202110824A (zh) | 2019-05-24 | 2021-03-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| CA3139554A1 (en) | 2019-05-31 | 2020-12-03 | Sage Therapeutics, Inc. | Neuroactive steroids and compositions thereof |
| AU2020395246A1 (en) | 2019-12-05 | 2022-06-16 | Sage Therapeutics, Inc. | A 19-nor C3,3-disubstituted C21-N-pyrazolyl steroid and methods of use thereof |
| EP4121438A2 (en) | 2020-03-18 | 2023-01-25 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| JP2023519241A (ja) | 2020-03-25 | 2023-05-10 | セージ セラピューティクス， インコーポレイテッド | 呼吸器状態の処置のための薬剤の使用 |
| US20230285417A1 (en) | 2020-07-20 | 2023-09-14 | Sage Therapeutics, Inc. | Formulations of 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
-
2017
- 2017-08-23 KR KR1020237017309A patent/KR20230079470A/ko not_active Application Discontinuation
- 2017-08-23 AR ARP170102330A patent/AR109393A1/es unknown
- 2017-08-23 BR BR112019003637A patent/BR112019003637A2/pt active Search and Examination
- 2017-08-23 JO JOP/2019/0022A patent/JOP20190022B1/ar active
- 2017-08-23 CA CA3034262A patent/CA3034262A1/en active Pending
- 2017-08-23 CN CN202210890024.3A patent/CN115974954A/zh active Pending
- 2017-08-23 EP EP21190443.8A patent/EP3981763A1/en active Pending
- 2017-08-23 EA EA201990565A patent/EA201990565A1/ru unknown
- 2017-08-23 PE PE2019000416A patent/PE20190915A1/es unknown
- 2017-08-23 CN CN202210890054.4A patent/CN115974956A/zh active Pending
- 2017-08-23 CN CN201780063826.4A patent/CN110088091A/zh active Pending
- 2017-08-23 MA MA046042A patent/MA46042A/fr unknown
- 2017-08-23 EP EP17761714.9A patent/EP3504189A1/en not_active Withdrawn
- 2017-08-23 WO PCT/US2017/048267 patent/WO2018039378A1/en active Application Filing
- 2017-08-23 JP JP2019510657A patent/JP2019524853A/ja not_active Withdrawn
- 2017-08-23 KR KR1020197008069A patent/KR20190040043A/ko not_active Application Discontinuation
- 2017-08-23 MX MX2019002193A patent/MX2019002193A/es unknown
- 2017-08-23 US US16/326,977 patent/US11236121B2/en active Active
- 2017-08-23 IL IL302480A patent/IL302480A/en unknown
- 2017-08-23 SG SG11201901445TA patent/SG11201901445TA/en unknown
- 2017-08-23 CN CN202210890025.8A patent/CN115974955A/zh active Pending
- 2017-08-23 AU AU2017315682A patent/AU2017315682B2/en active Active
- 2017-08-23 TW TW106128611A patent/TWI808945B/zh active
-
2019
- 2019-02-19 ZA ZA2019/01051A patent/ZA201901051B/en unknown
- 2019-02-21 PH PH12019500375A patent/PH12019500375A1/en unknown
- 2019-02-22 CL CL2019000477A patent/CL2019000477A1/es unknown
- 2019-02-22 MX MX2022007432A patent/MX2022007432A/es unknown
- 2019-03-20 CO CONC2019/0002596A patent/CO2019002596A2/es unknown
- 2019-03-22 EC ECSENADI201920141A patent/ECSP19020141A/es unknown
- 2019-12-10 CL CL2019003610A patent/CL2019003610A1/es unknown
-
2021
- 2021-08-06 US US17/396,464 patent/US11884696B2/en active Active
-
2022
- 2022-02-08 AU AU2022200811A patent/AU2022200811B9/en active Active
- 2022-04-08 AR ARP220100895A patent/AR125321A2/es unknown
- 2022-04-08 AR ARP220100894A patent/AR125320A2/es unknown
- 2022-11-07 JP JP2022178009A patent/JP2023002846A/ja active Pending
-
2023
- 2023-08-24 US US18/455,324 patent/US20230399357A1/en active Pending
-
2024
- 2024-02-06 AU AU2024200732A patent/AU2024200732A1/en active Pending
- 2024-05-07 JP JP2024075299A patent/JP2024097878A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003610A1 (es) | Un esteroide 19 nor-c21-n-pirazolilo c3,3-disustituido cristalino. (divisional solicitud 201900477). | |
| ECSP22012826A (es) | Inhibidores de parp1 | |
| DOP2023000077A (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| ECSP23012042A (es) | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este | |
| EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
| CL2019002270A1 (es) | Conjugados de anticuerpo y fármaco anti-egfr. (divisional solicitud 201803527) | |
| CR20170077A (es) | Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias | |
| CL2018002089A1 (es) | Maleato de agonista de tlr7, sus formas cristalinas c, d y e, sus procesos de preparación y su uso | |
| UY35275A (es) | Derivados de aminopirazina | |
| NI201500115A (es) | Estra-1,3,5(10), 16-tetraeno-3-carboxamidas para la inhibición de la 17b-hidroxiesteroide deshidrogenasa (akr1 c3) | |
| BR112017004000A2 (pt) | formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida | |
| MX2020004810A (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas. | |
| CL2020000334A1 (es) | Formas cristalinas de 2-[(2,4-diclorofenil)metil]-4,4-dimetil-isoxazolidin-3-ona. | |
| PH12020550537A1 (en) | Bicyclic sulfones and sulfoxides and methods of use thereof | |
| CY1125355T1 (el) | Πεντακυκλικη ενωση | |
| DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
| WO2019109067A3 (en) | Creatine prodrugs, compositions and methods of use thereof | |
| EA201990313A1 (ru) | Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека | |
| CO2019011980A2 (es) | Formas cristalinas de (s)-afoxolaner | |
| CL2020000439A1 (es) | Sales de un compuesto y sus formas cristalinas. | |
| CO2017005357A2 (es) | Un proceso para la fabricación de idalopirdina | |
| MX2019000977A (es) | Composiciones farmacéuticas a base de curcumina y procedimientos para su fabricación. | |
| UA114469U (xx) | ЗАСТОСУВАННЯ ПРЕПАРАТУ КАПІКОРУ (МЕЛЬДОНІЮ ДИГІДРАТУ І γ -БУТИРОБЕТАЇНУ ДИГІДРАТУ) ЯК НЕФРОПРОТЕКТОРНОГО ЗАСОБУ | |
| UA120519U (uk) | Використання похідних 4-амінобутанової кислоти як антиамнестичних засобів | |
| WO2017040980A3 (en) | Quinoxalinyl-piperazinamide methods of use |